Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human FDPS Antikörper:
anti-Rat (Rattus) FDPS Antikörper:
anti-Mouse (Murine) FDPS Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal FDPS Primary Antibody für IHC (p), WB - ABIN389054
Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ... in Proceedings of the National Academy of Sciences of the United States of America 2002
Show all 8 Pubmed References
Human Polyclonal FDPS Primary Antibody für IF, IHC (p) - ABIN1882080
Nomura, Miyajima, Sazuka, Tanaka, Kawarabayasi, Sato, Nagase, Seki, Ishikawa, Tabata et al.: Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature ... in DNA research : an international journal for rapid publication of reports on genes and genomes 1995
Show all 4 Pubmed References
mitochondrial targeting of FPS may be widespread among eukaryotes
Farnesyl diphosphate synthase (FPPS) of the dipteran Drosophila melanogaster has been cloned and its catalytic properties have been assessed.
These results are consistent with the previously proposed hypothesis that the allosteric pocket of human FPPS, located near the active site, plays a feed-back regulatory role for this enzyme.
our study indicated that DR patients have higher VEGF levels than diabetic patients without retinopathy, and -2578A/C (rs699947) and +405C/G (rs2010963) may be important factors in determining serum VEGF levels.
Results suggest that polymorphisms of the FDPS gene may influence the bone response to drugs targeting the mevalonate pathway, like statins.
A co-crystal structure of human farnesyl pyrophosphate synthase in complex with a bisphosphonate and two molecules of inorganic phosphate.
The results identify new classes of FPPS inhibitors, diterpenoids and sesquiterpenoids, that bind to the IPP (zeige IPP Antikörper) site and may be of interest as anticancer and antiinfective drug leads.
These observations suggest that an increase in the expression of endogenous FPPS could confer at least partial resistance to the pharmacological effect of N-BP drugs such as ZOL in vivo
LRP5 (zeige LRP5 Antikörper) and FDPS loci age-specifically affect skeletal traits in healthy fertile women.
Data indicate compounds represent a new structural class of farnesyl pyrophosphate synthase (hFPPS) inhibitors and suggest a development of therapeutics.
The iPA-driven modulation of FDPS can cause an enhancement of post-translational prenylation essential for the biological activity of key proteins in NK signaling and effector functions, such as Ras.
FPPS was more highly expressed in prostate cancer vs. normal prostate tissue. The association of FPPS with established histopathological risk parameters and biochemical recurrence implicates a contribution of the mevalonate pathway to PC progression.
Farnesyl pyrophosphate synthase (FPPS) may function as a potent regulator in myocardial remodelling. The FPPS-regulated signalling pathway is relevant to the pathological changes in cardiac hypertrophy and heart failure.
identified a single putative direct repeat 4 (DR4 (zeige HLADRB4 Antikörper)) LXR (zeige NR1H3 Antikörper) response element in the FPS (zeige FES Antikörper) promoter isolated from immortalized murine astrocyte P11 (zeige S100A10 Antikörper)-5 cells
This gene encodes an enzyme that catalyzes the production of geranyl pyrophosphate and farnesyl pyrophosphate from isopentenyl pyrophosphate and dimethylallyl pyrophosphate. The resulting product, farnesyl pyrophosphate, is a key intermediate in cholesterol and sterol biosynthesis, a substrate for protein farnesylation and geranylgeranylation, and a ligand or agonist for certain hormone receptors and growth receptors. Drugs that inhibit this enzyme prevent the post-translational modifications of small GTPases and have been used to treat diseases related to bone resorption. Multiple pseudogenes have been found on chromosomes 1, 7, 14, 15, 21 and X. Multiple transcript variants encoding different isoforms have been found for this gene.
farnesyl pyrophosphate synthase
, farnesyl diphosphate synthase
, farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)
, farnesyl pyrophosphate synthetase
, Farnesyl pyrophosphate synthetase
, (2E,6E)-farnesyl diphosphate synthase
, FPP synthase
, FPP synthetase
, farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase
, CR 39
, cholesterol-regulated 39 kDa protein
, farnesyl diphosphate synthetase
, testis-specific farnesyl pyrophosphate synthetase
, 6E)-farnesyl diphosphate synthase
, geranylgeranyl-diphosphate synthase